CA-NETAPP
12.5.2022 14:02:09 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the results of the annual Cloud Infrastructure Report based on a survey of public cloud business and IT decision makers. The report from Spot by NetApp, continuing the annual survey previously conducted by CloudCheckr following its acquisition by NetApp, highlights the current state of cloud management and how organizations are working to optimize their environments.
A key trend surfaced in the report highlighted that while companies continue to accelerate cloud adoption, many do not believe they are effectively optimizing their infrastructure. Businesses are addressing this through the development of internal programs such as Cloud Centers of Excellence (CCoEs) and FinOps, cloud purchase commitments, tools, and external help (e.g., managed service providers). While several respondents indicated that they are still maturing in these areas, those that have successfully deployed and scaled programs report improved agility, efficiency, and governance in their cloud journey.
“The results highlight that while companies have rapidly adopted cloud, IT continues to look for ways to increase the value and ROI of its cloud investments,” said Anthony Lye, Executive Vice President and General Manager, Public Cloud Services at NetApp. “Organizations also make it clear that cloud cost, security, automation, and resource optimization will remain key concerns. Cloud-centric companies most likely to succeed will implement the right strategies, technology solutions and partner relationships to help manage costs and reduce complexity.”
Key Findings from Spot by NetApp’s 2022 Cloud Infrastructure Report:
Cloud and cost management is still a work in progress
- Confidence in visibility into public cloud costs has dropped in the past year; 21 percent were “very” confident in 2022, down from 31 percent in 2021.
- 62 percent of respondents will focus on cost management in 2022.
- 96 percent say FinOps is important to cloud success, but only 10 percent have a mature FinOps practice.
As investment in public cloud infrastructure deepens and the number of cloud users matures, there must be careful consideration of the business value gained from these resources. The continued focus on improving cost management this year—and the role of FinOps to help do this—is even more critical for larger enterprises.
Managing cloud operations in 2022 will grow in scope
- 2022 transformation goals include increasing the use of cloud technology (63 percent), migrating additional services to the cloud (52 percent), and optimizing cloud costs (50 percent).
- 90 percent report they have or plan to have a Cloud Center of Excellence (CCoE).
- 61 percent of those who currently have a CCoE say that their responsibilities will grow in 2022.
Enterprises must continue to take steps even after migrating to the cloud to optimize their cloud investment. Those with a more mature CCoE practice reported seeing greater benefit and value compared to those with less established CCoEs.
MSPs play a key role in cloud operations
- 71 percent use an MSP for their cloud operations.
- 100 percent of companies that work with an MSP for cloud operations say that they have benefited from that relationship.
- 83 percent of companies that work with an MSP for cloud operations rely on them for their FinOps practice.
When MSPs take a more significant leadership role in operating their clients’ cloud environments, IT organizations report seeing greater value. This reflects the impact of MSPs’ investments in developing their cloud operational services, such as cost optimization, security, compliance, and asset management.
Methodology
In February 2022, an online survey was sent to independent sources of IT and business stakeholders responsible for public cloud infrastructures such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud. A total of 305 respondents completed the survey. Participants represented a wide range of roles, company sizes, industries, and job levels. Certain questions were repeated from similar 2017, 2019, and 2021 studies to investigate changing trends.
Additional Resources
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005238/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom